‘Ozempic mouth' and ‘Ozempic teeth' can be frightening — here's the No. 1 way to protect your smile
GLP-1 drugs like Ozempic and Mounjaro can be a wild ride — users may experience dramatic weight loss and a sharp drop in appetite but also fierce bouts of nausea, vomiting or diarrhea.
There's one possible complication that shouldn't be brushed off. GLP-1 meds, which promote feelings of fullness by mimicking a naturally occurring hormone, can significantly impact oral health.
This phenomenon is known as 'Ozempic mouth' or 'Ozempic teeth.'
'Much of this revolves around the side effect of dry mouth,' Dr. Elizabeth Walton, co-founder and clinical director of Risas Kids Dental in Phoenix, told The Post.
'With dry mouth, you have increased likelihood of dental decay and periodontal disease.'
Walton fills us in on ways that Ozempic-like drugs can menace the mouth — and how to get to the root of the issue.
Saliva neutralizes acid, washes away food particles and remineralizes tooth enamel, providing a lot of natural protection against sugars in our mouths.
GLP-1 drugs can influence salivary gland function and decrease saliva production. They are also known to reduce thirst, further diminishing saliva production.
'When the oral environment dries up, bacteria have a great time in there, causing decay and increased inflammatory response,' Walton explained.
'The increased inflammatory response has a direct impact on gingival health — meaning you are more likely to have problems with gingivitis and periodontitis.'
Gingivitis is inflammation of the gums, while periodontitis is a more advanced and destructive form of gum disease.
Dry mouth symptoms can range from mild to rather severe. To avoid having to undergo a painful deep cleaning or gum surgery, Walton's top tip is to drink more water.
She recommends consuming between 2 and 3 liters of H2O a day, which translates to about 64 to 100 ounces. Sugar-free gum also helps promote saliva production.
Biotène, meanwhile, offers a range of products designed to help manage dry mouth symptoms, including a mouth spray, oral rinse, moisturizing gel and lozenges.
'I found the Biotène gel to be best,' Walton said. 'But I had to carry it with me because the effects only lasted a short period of time.'
GLP-1 users should also avoid dehydrating foods and beverages like caffeinated drinks, alcohol, sports refreshments, salty foods, cured meats, asparagus and sugary juices.
And beware spicy foods, which can irritate a dry mouth.
Another issue with GLP-1 drugs is that they can cause intense gastrointestinal struggles.
'Nausea and vomiting have a massive impact on oral health, just like dry mouth,' Walton said.
'After you vomit, the pH in your mouth decreases significantly enough to make you more susceptible to decay.'
She suggests not brushing your teeth after you vomit. Yes, you read that right.
Saliva continuously produces a natural protective barrier for your teeth called the dental pellicle.
Brushing your teeth brushes that away, making your teeth even more vulnerable to the newly acidic environment of your mouth.
Acidic substances can be quite harmful, eroding the protective enamel of your teeth and paving the way for increased sensitivity, discoloration and a higher risk of cavities.
'It takes between one to two hours for the pH in your mouth to regain optimal levels after vomiting,' Walton said.
'So, if you get sick, rinse with water,' she added. 'Drink a lot of water — you will be dehydrated anyway because of the medication and now you just puked — and brush your teeth after a couple hours.'
And finally, GLP-1 drugs can cause changes in taste.
Food may not taste as good as it used to — or the meds leave a metallic or bitter taste in your mouth, which is known as 'Ozempic tongue.'
'Some of these symptoms will not go away, but luckily, you won't be taking the GLP-1 forever,' Walton said.
The metallic taste may be due to changes in saliva production, mild ketosis or bile reflux. Walton advises sugar-free gum to increase saliva production and 'confuse your brain out of perceiving the metal taste.'
Remember to talk with your healthcare provider about any side effects you experience while taking GLP-1 drugs.
'To be successful in your weight loss, you should enlist as much support as possible,' Walton said. 'Don't forget your dentist! We can help it be easier and safer for you.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
4 hours ago
- Newsweek
Men Are Gaining More Confidence From Ozempic Than Women: Report
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. While some may associate Ozempic and other GLP-1 medications with women trying to lose weight, it turns out that men are the ones gaining the most significant confidence boosts from it. In a Kinsey Institute and survey of GLP-1 users, men were three times more likely than women to say GLP-1s gave them more confidence. They also experienced more notable improvements in their dating lives and libidos. Why It Matters In recent years, the use of weight-loss medications called glucagon-like peptide-1 (GLP-1) receptor agonists has surged. Popular products include Ozempic, Mounjaro, Wegovy and Zephound and have been a game changer for many Americans who are obese or have type 2 diabetes. For patients who successfully lose weight, there can be significant changes in their mental health as well as their personal dating lives, but this impact appears to be more pronounced among male users. Ozempic is medicine for adults with type 2 diabetes. Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia. Ozempic is medicine for adults with type 2 diabetes. Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia. Steve Christo - Corbis/Corbis via Getty Images What To Know Across the entire survey sample, drugs like Ozempic were having major effects on users' dating lives. While 59 percent of users said the drugs changed their dating experiences, men experienced a more notable impact on their confidence levels and sex lives, according to the report. Men were three times more likely than women to say GLP-1s boosted their confidence and two times more likely to say they were going on more dates. They also reported higher libido, more matches and increased sexual activity. Still, there were some negative implications for men, of which 60 percent said they feared being judged for using GLP-1s and worried they'd be seen as "less masculine" for doing so. Of all GLP-1 users surveyed, 12 percent said they were going on more dates, and 14 percent said they were getting more matches on dating apps. Meanwhile, a whopping 52 percent reported changes in their sex lives. What People Are Saying Dr. Justin Lehmiller, the Kinsey Institute study lead, said in a statement: "I think there's a very nuanced story to tell here. How these drugs impact your sex life will depend on a variety of factors, including drug dosage and drug type, speed of weight loss, starting and ending weight, and how much you changed your health and fitness habits at the same time." "Sexually speaking, it appears that men are experiencing more positive and more negative impacts of GLP-1 medications." What Happens Next The long-term implications of GLP-1 medication use are so far unclear. A recent study discovered a new link between taking GLP-1 drugs and elevated risk of pancreatitis and kidney conditions, including kidney stones. GLP-1 medications are also associated with a higher risk of digestive problems, including nausea, vomiting, diarrhea, and even stomach paralysis in rare cases.
Yahoo
4 hours ago
- Yahoo
Hims & Hers Health, Inc. (HIMS) Announces Expansion To Canada
Hims & Hers Health, Inc. (NYSE:HIMS) is among the 13 Best Booming Stocks to Buy Now. On July 9, the digital health and wellness platform announced plans to expand in Canada by offering generic semaglutide. A nurse in a telehealth platform talking with a patient on video call for consultation. This comes at a time when Novo Nordisk is set to lose its patent protection on Ozempic and Wegovy in Canada for not paying a maintenance fee in 2019. Hims & Hers Health, Inc. (NYSE:HIMS) joins a growing list of companies that are capitalizing on Novo Nordisk's lapsed patent on its GLP-1s. The introduction of generics is a pivotal moment for Canada's healthcare industry. With about two-thirds of adults in the country being overweight or obese, access to treatments has remained elusive for many due to the high costs. Hims & Hers Health, Inc. (NYSE:HIMS) intends to offer generic semaglutide at a significant discount to the currently branded versions, with prices expected to further decrease over time. Hims & Hers Health, Inc. (NYSE:HIMS)'s decision to enter the Canadian market follows the company's acquisition of European telehealth platform, Zava, in June, which will expand its services to France, Germany, and Ireland, and grow its active customer base by approximately 50%. While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best German Stocks to Invest in Now and Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
What causes obesity? A major new study is upending common wisdom.
Obesity is uncommon among Hadza hunter-gatherers in Tanzania, Tsimane forager-farmers in Bolivia, Tuvan herder-farmers in Siberia, and other people in less-developed nations. But it's widespread among those of us in wealthy, highly industrialized nations. Why? A major study published this week in PNAS brings surprising clarity to that question. Using objective data about metabolic rates and energy expenditure among more than 4,000 men and women living in dozens of nations across a broad spectrum of socioeconomic conditions, the study quantified how many calories people from different cultures burn most days. Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. For decades, common wisdom and public health messaging have assumed that people in highly developed nations, like the United States, are relatively sedentary and burn far fewer daily calories than people in less-industrialized countries, greatly increasing the risk for obesity. But the new study says no. Instead, it finds that Americans, Europeans and people living in other developed nations expend about the same number of total calories most days as hunter-gatherers, herders, subsistence farmers, foragers and anyone else living in less-industrialized nations. That unexpected finding almost certainly means inactivity is not the main cause of obesity in the U.S. and elsewhere, said Herman Pontzer, a professor of evolutionary anthropology and global health at Duke University in North Carolina and a senior author of the new study. What is, then? The study offers provocative hints about the role of diet and some of the specific foods we eat, as well as about the limits of exercise, and the best ways, in the long run, to avoid and treat obesity. - - - Is diet or inactivity causing obesity? 'There's still a lively debate in public health about the role of diet and activity' in the development of obesity, Pontzer said, especially in wealthy nations. Some experts believe we're exercising too little, others that we're eating too much, and still more that the two contribute almost equally. Understanding the relative contributions of diet and physical activity is important, Pontzer noted, because we can't effectively help people with obesity unless we first tease out its origins. But few large-scale studies have carefully compared energy expenditure among populations prone to obesity against those more resistant to it, which would be a first step toward figuring out what drives weight gain. So, for the new study, Pontzer and his 80-plus co-authors gathered existing data from labs around the world that use doubly labeled water in metabolism studies. Doubly labeled water contains isotopes that, when excreted in urine or other fluids, allow researchers to precisely determine someone's energy expenditure, metabolic rates and body-fat percentage. It's the gold standard in this kind of research. They wound up with data for 4,213 men and women from 34 countries or cultural groups, running the socioeconomic gamut from tribes in Africa to executives in Norway. They calculated total daily energy expenditures for everyone, along with their basal energy expenditure, which is the number of calories our bodies burn during basic, biological operations, and physical activity energy expenditure, which is how many calories we use while moving around. - - - A new theory of how our metabolisms work After adjusting for body size (since people in wealthy nations tend to have larger bodies, and larger bodies burn more calories), they started comparing different groups. Anyone expecting a wide range of energy expenditures, with hunter-gatherers and farmer-herders at the high end and deskbound American office workers trailing well behind, would be wrong. Across the board, the total daily energy expenditures of the 4,213 people were quite similar, no matter where they lived or how they spent their lives. Although the hunter-gatherers and other similar groups moved around far more throughout the day than a typical American, their overall daily calorie burns were nearly the same. The findings, though counterintuitive, align with a new theory about our metabolisms, first proposed by Pontzer. Known as the constrained total energy expenditure model, it says that our brains and bodies closely monitor our total energy expenditure, keeping it within a narrow range. If we start consistently burning extra calories by, for instance, stalking prey on foot for days or training for a marathon, our brains slow down or shut off some tangential biological operations, often related to growth, and our overall daily calorie burn stays within a consistent band. - - - The role of ultra-processed foods The upshot is that 'there is no effect of economic development on size-adjusted physical activity expenditure,' Pontzer says. In which case, the fundamental problem isn't that we're moving too little, meaning more exercise is unlikely to reduce obesity much. What could, then? 'Our analyses suggest that increased energy intake has been roughly 10 times more important than declining total energy expenditure in driving the modern obesity crisis,' the study authors write. In other words, we're eating too much. We may also be eating the wrong kinds of foods, the study also suggests. In a sub-analysis of the diets of some of the groups from both highly and less-developed nations, the scientists found a strong correlation between the percentage of daily diets that consists of 'ultra-processed foods' - which the study's authors define as 'industrial formulations of five or more ingredients' - and higher body-fat percentages. We are, to be blunt, eating too much and probably eating too much of the wrong foods. 'This study confirms what I've been saying, which is that diet is the key culprit in our current [obesity] epidemic,' said Barry Popkin, a professor at the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill and an obesity expert. 'This is a well-done study,' he added. Other experts agree. 'It's clear from this important new research and other studies that changes to our food, not our activity, are the dominant drivers of obesity,' said Dariush Mozaffarian, director of the Food is Medicine Institute at Tufts University in Boston. The findings don't mean, though, that exercise is unimportant, Pontzer emphasized. 'We know that exercise is essential for health. This study doesn't change that,' he said. But the study does suggest that 'to address obesity, public health efforts need to focus on diet,' he said, especially on ultra-processed foods, 'that seem to be really potent causes of obesity.' Related Content He may have stopped Trump's would-be assassin. Now he's telling his story. He seeded clouds over Texas. Then came the conspiracy theories. How conservatives beat back a Republican sell-off of public lands
